Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis

Area of Science:

• Dermatology and Immunology
• Cardiology and Metabolic Health

Background:

• Psoriasis is a chronic inflammatory skin condition with systemic implications.
• Significant evidence links psoriasis to increased cardiometabolic comorbidities, including cardiovascular diseases (CVDs), obesity, diabetes mellitus, and metabolic syndrome.
• The risk of these comorbidities correlates with psoriasis severity.

Purpose of the Study:

• To review the association between cardiometabolic comorbidities and psoriasis.
• To explore the benefits and precautions of biologic therapy in managing psoriasis patients with cardiometabolic comorbidities.
• To elucidate the pathogenic mechanisms underlying cardiometabolic comorbidities in psoriasis.

Main Methods:

• Review of clinical trials and existing literature.
• Analysis of pathogenic mechanisms including genetic factors, lipid metabolism, insulin resistance, and inflammatory pathways (TNF-α, IL-23/Th-17).

Main Results:

• Biologic therapies targeting inflammatory pathways show promise in improving psoriasis quality of life.
• These therapies may reduce the incidence of cardiometabolic comorbidities in psoriasis patients.
• Shared inflammatory pathways and metabolic dysregulation contribute to the comorbidity link.

Conclusions:

• Biologic therapy is a valuable tool for managing psoriasis, with potential benefits for associated cardiometabolic conditions.
• Careful consideration of benefits and precautions is essential when using biologic therapy in patients with cardiometabolic comorbidities.
• Understanding shared pathogenic mechanisms is key to comprehensive patient management.